CDKN2A and acute lymphoblastic leukemia: 1,25(OH)2VD3 actively induced bone marrow stroma to release CXCL12 in vitro, and increased CXCL12 serum levels in vivo, resulting in an increased ability to attract the BCR-ABL+ Arf−/− ALL to the marrow and support its growth.